News & Events
CPHI Milan 2026 | Lianhe Aigen: Two Engines, A New Chapter

CPHI Milan 2026 | Lianhe Aigen: Two Engines, A New Chapter

Oct. 09, 2026

From a solid foundation to dual-engine momentum, Lianhe Aigen is opening a new chapter — with its well-established small molecule business as the ballast, its fast-growing oligonucleotide business as the growth engine, and proven capabilities in peptides and linkers, the company is building an integrated, multi-modality, one-stop CRDMO platfor

Review of Lianhe Aigen's 3rd Quality Month | Fostering Learning Through Competition, Building Defenses Through Action

Review of Lianhe Aigen's 3rd Quality Month | Fostering Learning Through Competition, Building Defenses Through Action

Oct. 08, 2026

To solidify the foundation of quality knowledge across the workforce and strengthen compliance awareness in all roles, Lianhe Aigen recently concluded its 3rd Quality Month series under the theme "Quality from Dedication, Expertise Driving Growth." Spanning multiple dimensions.

Lianhe Aigen Deepens Domestic Collaboration, Achieving Key Substantive Breakthrough in CRDMO Business

Lianhe Aigen Deepens Domestic Collaboration, Achieving Key Substantive Breakthrough in CRDMO Business

Sep. 30, 2026

Recently, the Drug Marketing Authorization Application for an innovative drug API, jointly developed by Lianhe Aigen and a key domestic pharmaceutical partner, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).

Proud to Announce | Lianhe Aigen Awarded EcoVadis Platinum Medal, Ranking in the Top 1% Globally

Proud to Announce | Lianhe Aigen Awarded EcoVadis Platinum Medal, Ranking in the Top 1% Globally

Sep. 10, 2026

Lianhe Aigen has been awarded the Platinum Medal in the latest assessment by EcoVadis, a globally recognized sustainability rating agency, placing the company among the top 1% of all companies assessed worldwide.

Groundbreaking Ceremony for the First Large-Scale High-End Synthesizer of the Strategic Project I Anchoring Q3 with New Equipment to Drive the Campaign

Groundbreaking Ceremony for the First Large-Scale High-End Synthesizer of the Strategic Project I Anchoring Q3 with New Equipment to Drive the Campaign

Aug. 11, 2026

The newly unveiled synthesizer serves as the core hub of the strategic production line, undertaking key synthesis processes and quality control functions.

Consolidating the Foundation in Small Molecules, Setting Sail for the Future of Oligonucleotides

Consolidating the Foundation in Small Molecules, Setting Sail for the Future of Oligonucleotides

Jul. 20, 2026

As a trusted partner in the small-molecule CDMO space, we continue to strengthen our core business while proactively expanding into new frontiers—including oligonucleotide therapeutics—to build a more diversified service capability matrix.

How Can We Help You?

We provide customers with one-stop CRDMO services covering the entire lifecycle of drugs.

Introduction

We use cookies on our website to better understand how you use our website. For more information about how we use cookies, please visit our Terms of Use and Legal Notices and Privacy Statement and Cookies Policy. By continuing to use this website without changing your settings, you will be deemed to have consented to our use of cookies.